Today: 3 May 2025
7 March 2024
3 mins read

AstraZeneca plans £650 mn investment in UK

The plans outlined today are the latest step in the wider plan to deliver the long-term change that Britain needs – to deliver a brighter future and improve economic security and opportunity for everyone…reports Asian Lite News

Pharmaceutical firm AstraZeneca on Wednesday outlined plans to invest £650 million in the UK – helping boost the UK’s world leading Life Sciences sector and grow the economy. This significant investment will enhance public health protection and pandemic preparedness.  

AstraZeneca intends to invest £450 million at their manufacturing site in Speke, Liverpool for the research, development, and manufacture of vaccines – building on the site’s current role in supplying the world leading childhood vaccination programme. The new facility will be designed and built to be operationally net zero with power supplied from renewable energy sources.

In a further boost for the UK’s resilience for future pandemics and global health threats, AstraZeneca and the UK Health Security Agency (UKHSA) plan to work in partnership to advance science for developing and evaluating vaccines – using technology from both AstraZeneca’s manufacturing site in Speke and the UKHSA’s Vaccine Development Evaluation Centre (VDEC) at their Porton Down site.

AstraZeneca will also expand its presence at Europe’s largest life sciences cluster in Cambridge with £200 million in investment. The facility will house around 1,000 employees and will be adjacent to its £1.1 billion global R&D Discovery Centre (DISC), which already hosts 2,300 researchers and scientists. These jobs will provide opportunities for people looking to get the skills they need to succeed in life and – with cuts to National Insurance – enjoy more money in their pocket as a result of their hard work.

To drive investment and growth, the UK Government has delivered one of the most competitive business tax regimes of any major economy – sticking to an economic plan to build a stronger economy where hard work is rewarded, and ambition and aspiration are celebrated. Full expensing is one of the biggest business tax cuts in modern British history, giving the UK the most generous regime for capital allowances in the G7 and joint most generous in the OECD.

The plans outlined today are the latest step in the wider plan to deliver the long-term change that Britain needs – to deliver a brighter future and improve economic security and opportunity for everyone. This demonstrates the vast Life Sciences expertise and capability in this country and will further strengthen AstraZeneca’s UK footprint. The company will also open a new manufacturing facility for one of its cancer medicines in Macclesfield later this year, following the announcement of a £380 million investment in 2021.

Chancellor Jeremy Hunt said, “To drive investment we’ve delivered one of the most competitive business tax regimes of any major economy, as part of our plan to help our key industries to grow. Our £108 billion Life Sciences sector provides over 300,000 high skilled jobs across the UK and is crucial for the country’s health, wealth and resilience. We are sticking to our plan to make the UK one of the best places in world to invest in developing and manufacturing new, innovative medicines – both protecting public health and growing our economy. AstraZeneca’s investment plans are a vote of confidence in the attractiveness of UK as a Life Sciences superpower and strengthen our resilience for future health emergencies.”

AstraZeneca Chief Executive Officer, Sir Pascal Soriot, said, “AstraZeneca’s planned investment would enhance the UK’s pandemic preparedness and demonstrates our ongoing confidence in UK life sciences.  We will continue to support the UK in driving innovation and patient access, building on the strong foundations which have been put in place. This year marks 25 years since the merger of UK-based Zeneca Group and Swedish Astra AB. We are proud of our British roots and how far we have come over that time – we are now a truly global company that has transformed the lives of millions of patients throughout the world with a relentless focus on science and innovation.”

ALSO READ-‘Chinese Lab Mapped Covid Virus Weeks Prior’

Previous Story

Starmer says budget is ‘bereft of ideas’

Next Story

China, Russia planning nuclear power plant on Moon

Latest from -Top News

WAVES 2025: Jaishankar Advocates Cultural Pluralism

External Affairs Minister S. Jaishankar delivered a powerful address at the WAVES 2025 Global Media Dialogue, highlighting the significance of cultural pluralism in shaping global change. Speaking on the second day of

Abu Dhabi, Beirut Reconnect 

A key highlight of Aoun’s visit to UAE was the agreement to ease travel restrictions between the two countries — a move set to facilitate the movement of citizens and promote closer

Putin lauds UAE’s role in prisoner swaps 

His Highness Sheikh Mohamed bin Zayed and President Vladimir Putin reaffirm growing partnership amid UAE’s humanitarian role in Ukraine conflict  In a strong display of strategic diplomacy and humanitarian leadership, President His

ATM 2025 sets new standard 

The global event drew over 55,000 travel and tourism professionals from 166 countries, marking a 16% year-on-year increase in attendance and cementing Dubai’s role as a key hub for shaping the future
Go toTop

Don't Miss

UAE Minister Explores Financial Ties With UK Trade Envoy

Both parties highlighted the rooted diplomatic relations between the UAE

UK govt stops lower duty access for $1 bn exports

Goods such as bicycles exported from India are also expected